Biophan to Receive Nano 50 ``Best of the Best'' Award for Innovation
in Nanotechnology at NASA Tech Briefs Conference; CEO to Present
Biophan's Nanotechnology Development Initiatives at Nano 2005 Forum in
Boston

ROCHESTER, N.Y.--(BUSINESS WIRE)--Nov. 9, 2005--Biophan Technologies,
Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation
biomedical technology, announced today that it will receive a "Best of
the Best" award from Nanotech Briefs magazine this week as part of its
first annual Nano 50 Awards contest to recognize superior scientific
achievement and innovation. In addition, CEO Michael Weiner will
present the Company's nanotechnology strategic initiatives.


The official ceremony will take place at an awards dinner during the
NASA Tech Briefs Nano 2005 conference November 10-11, to be held at
the Marriot Boston Newton in Newton, MA. Biophan is being recognized
for an innovative nanomaterial-based biothermal power source. Being
developed by Biophan subsidiary TE-Bio, the biothermal power source
converts body heat into electricity to power implantable medical
devices.

"Biophan's research includes cutting-edge development in biomedical
applications of nanotechnology," said Mr. Weiner. "The Nano 50 "Best
of the Best" award recognizes one of our important development
programs. We believe the Company will continue to demonstrate
leadership in other market segments, such as MRI imaging and
drug-delivery systems, through our nanotechnology-based solutions."

Biophan's TE-Bio subsidiary has an agreement with NASA for
characterization and joint development of high-density, thermoelectric
nanomaterials for use with implantable medical devices. Research is
being jointly conducted by Biophan and NASA personnel at the NASA Ames
Research Center for Nanotechnology in Moffett Field, CA.

Mr. Weiner will also make a special presentation of the Company's
portfolio of nanotechnology-based biomedical applications on November
10th at 2:00 p.m., in Ballroom A-D. Biophan's nanotechnology solutions
span a range of existing and emerging multi-billion-dollar markets in
addition to the biothermal power source, such as drug-delivery and MRI
safety and image compatibility of medical devices.

The nominations for the Nano 50 were judged by a panel of
nanotechnology and MEMS experts. The technologies, products, and
innovators receiving the 50 highest scores were named winners of the
Nano 50 "Best of the Best" awards. Presented by Nanotech Briefs
magazine, a digital publication from the publishers of NASA Tech
Briefs, the Nano 50 recognizes the top 50 technologies, products, and
innovators that have significantly impacted, or are expected to
impact, the state of the art in nanotechnology.

About Nanotech Briefs

Nanotech Briefs, launched in January 2004, is a digital (PDF format)
magazine from the publishers of NASA Tech Briefs - the country's
largest-circulation design engineering magazine - that provides the
best of government, industry and university nanotech innovations with
real-world applications in areas such as electronics, materials,
sensors, manufacturing, biomedical, optics/photonics, and
aerospace/defense. Nanotech Briefs is the first small-tech publication
specifically for design engineers who are designing tomorrow's
nanotech products today. For more information, please visit
www.nanotechbriefs.com. For more information on the NASA tech briefs
Nano 2005 Boston conference, please visit
http://www.techbriefs.com/nano/agenda.html

About Biophan Technologies

Biophan develops and markets a broad spectrum of next-generation
technologies and products with commercial applications in a variety of
multibillion-dollar healthcare market segments. Committed to growth
through innovation and developmental leadership, Biophan and its
licensors now hold a total of 156 U.S. patents, licenses, and
applications. This extensive intellectual property portfolio includes
nanotechnology-based and other approaches to create enhancements for
several medical products. Biophan's technology portfolio includes
solutions developed to enable implanted medical systems such as
pacemakers, interventional surgical devices such as catheters and
guidewires, and implants such as stents to be safely and effectively
imaged by Magnetic Resonance Imaging (MRI) systems. Biophan is
developing these same technologies to enable new MRI contrast agents.
Other applications include drug delivery and power systems which
derive energy from body heat. Biophan's intellectual property
portfolio now includes 42 issued U.S. patents, 8 recently-allowed
applications that will issue as patents in the near future, and 106
pending applications at various stages of examination at the U.S.
Patent and Trademark Office, plus international applications. The
patents cover areas including nanotechnology, medical device designs,
radio frequency filters, thermoelectric materials and optical catheter
technologies. Biophan has joint development and licensing agreements
with Boston Scientific and NASA's Ames Center for Nanotechnology.
Biophan's goal is to make all biomedical devices capable of safely and
effectively working with MRI, and to deliver other technologies which
will improve the delivery of healthcare. Biophan is also listed on the
Frankfurt Stock Exchange under the ticker symbol "BTN." For more
information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute
forward-looking statements within the meaning of applicable securities
laws. These statements reflect what Biophan anticipates, expects, or
believes may happen in the future. Biophan's actual results could
differ materially from the outcome or circumstance expressed or
implied by such forward-looking statements as a result of a variety of
factors including, but not limited to: Biophan's ability to develop
its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development
programs; the ability of Biophan to demonstrate the effectiveness of
its technology; the acceptance by the market of Biophan's technology
and products incorporating such technology, the ability of Biophan to
effectively negotiate and enter into contracts with medical device
manufacturers for the licensing of Biophan's technology; competition;
the ability of Biophan to raise capital to fund its operating and
research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to
time in Biophan's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read
in conjunction with Biophan's periodic filings with the SEC which are
incorporated herein by reference. The forward-looking statements
contained herein are made only as of the date of this press release,
and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.